The Short Answer
Wegovy (semaglutide) and Zepbound (tirzepatide) are the two most effective FDA-approved weight loss medications. Zepbound's dual GIP/GLP-1 mechanism produces more weight loss in trials (~22.5% vs ~15%), but both are excellent options. The choice often comes down to insurance, availability, and individual response.
Side-by-Side Comparison
| Feature | Wegovy | Zepbound |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Drug Class | GLP-1 Agonist | GIP/GLP-1 Dual Agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA Approval | Weight Management | Weight Management |
| Max Dose | 2.4 mg weekly | 15 mg weekly |
| Administration | Weekly injection | Weekly injection |
| Avg Weight Loss | ~15% | ~22.5% |
| Titration Steps | 5 steps over 16+ weeks | 6 steps over 20+ weeks |
Key Differences
- Zepbound produces ~50% more weight loss than Wegovy in clinical trials (22.5% vs 15% of body weight)
- Wegovy has been on the market longer and has more long-term safety data
- Both require weekly injections, but the pen devices and dose escalation schedules differ
- Insurance coverage and availability fluctuate for both — check with your provider and pharmacy
- Zepbound's dual mechanism may cause slightly more GI side effects during titration
Which Should You Choose?
🎯
Choose Wegovy
Choose Wegovy if you want a well-established weight loss medication with a longer track record, or if your insurance covers it better. It's an excellent choice for steady, significant weight loss (~15%).
Full Wegovy Guide⚡
Choose Zepbound
Choose Zepbound if you want the maximum weight loss available from any GLP-1 medication (~22.5%). Its dual mechanism is the most effective currently available for chronic weight management.
Full Zepbound Guide